Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
The latest developments in one of the US FDA's favorite pathways.
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.